

Haematologica
HAEMATOL/2016/142976
Version 3

Targeted positron emission tomography imaging of CXCR4 expression
in patients with acute myeloid leukemia

Peter Herhaus, Stefan Habringer, Kathrin Philipp-Abbrederis, Tibor Vag, Carlos Gerngross, Margret Schottelius, Julia Slotta-Huspenina, Katja Steiger, Torben Altmann, Tanja Weisser, Sabine Steidle, Markus Schick, Laura Jacobs, Jolanta Slawska, Catharina Mueller-Thomas, Mareike Verbeek, Marion Subklewe, Christian Peschel, Hans-Juergen Wester, Markus Schwaiger, Katharina Goetze, and Ulrich Keller

Disclosures: Hans-Juergen Wester is CEO of Scintomics, the distributor of Pentixafor.

Contributions: Peter Herhaus and Kathrin Philipp-Abbrederis recruited patients and analyzed patient data. Stefan Habringer, Tanja Weisser, Markus Schick, Jolanta Slawska, Laura Jacobs and Sabine Steidle performed experiments (cell culture, flow cytometry, xenograft experiments). Carlos Gerngross and Tibor Vag performed PET/MR/CT analyses. Margret Schottelius and Hans-Juergen Wester generated the PET tracer Pentixafor and performed tracer labeling. Julia Slotta-Huspenina and Katja Steiger performed histological analysis. Catharina Mueller-Thomas, Mareike Verbeek, Torben Altmann and Marion Subklewe referred patients and provided patient data. Katharina Goetze provided flow cytometric expertise and performed data analysis. Christian Peschel, Markus Schwaiger and Ulrich Keller designed the research that was supervised by Ulrich Keller. Stefan Habringer, Peter Herhaus, Katharina Goetze and Ulrich Keller wrote the manuscript.